stock.name

Neurocrine Biosciences, Inc.

NBIX

Market Cap$13.19B
Close$

Compare Neurocrine Biosciences

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Neurocrine Biosciences, Inc.Neurocrine Biosciences, Inc.52.80%11%7.70.1
marketMarket Avg591.3%30%-1
HealthcareHealthcare Avg64.41.34%15%-0.9
$200.00

Target Price by Analysts

43.9% upsideNeurocrine Biosciences Target Price DetailsTarget Price
$240.08

Current Fair Value

72.8% upside

Undervalued by 72.8% based on the discounted cash flow analysis.

Share Statistics

Market cap$13.19 Billion
Enterprise Value$12.33 Billion
Dividend Yield$0.0 (0.0%)
Earnings per Share$2.47
Beta0.37
Outstanding Shares99,507,000
Avg 30 Day Volume876,913

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio52.82
PEG80.08
Price to Sales7.72
Price to Book Ratio6.32
Enterprise Value to Revenue6.53
Enterprise Value to EBIT31.22
Enterprise Value to Net Income49
Total Debt to Enterprise0.01
Debt to Equity0.08

Revenue Sources

No data

ESG Score

No data

About Neurocrine Biosciences, Inc.

CEO: Kevin Gorman